Conversion to Resection

Intera 3000 for Patients with Unresectable Colorectal Liver Metastases (CLM)

Treatment with the Intera 3000 Pump and floxuridine combined with systemic chemotherapy can reduce tumor burden and enable previously unresectable CLM to be successfully removed. Conversion to resection is a key factor in increasing overall survival in patients with CLM.

According to a study at Memorial Sloan Kettering, 47% of patients with unresectable liver metastases who received an Intera 3000 pump with floxuridine and systemic chemotherapy were able to be surgically resected following treatment.

Adjuvant Therapy

In this prospective phase II trial of 49 Patients with unresectable CLM who were treated with the Intera 3000 Pump and floxuridine and systemic chemotherapy:

  • 47% of patients were able to be surgically resected.
  • 3-year survival for patients who underwent resection was 80%.
  • The overall response rate was 76%, with 36 partial and 1 complete response.
  • The response rate in chemotherapy naïve patients (17 of 49) was 82%, which included 1 complete response.
  • The response rate in patients receiving the Intera 3000 as second-line (21 of 49) and third-line (11 of 49) therapy was 72%.
  • The median number of tumors in the liver was 14 (range of 7 to 23).
  • Study limitations: The enrolled patients represent a unique population of relatively young patients with good functional status who presented with extensive and heavily pretreated disease, and treated at a single specialized cancer center. Furthermore, conversion to resection is a somewhat subjective end point that depends on the skill and experience of the treating surgeon.[1]

 

[1] D’Angelica MI, Correa-Gallego C, Paty PB, et al:  Phase II Trial of Hepatic Artery Infusional and Systemic Chemotherapy for With Unresectable Hepatic Metastases From Colorectal Cancer Conversion to Resection and Long-term Outcomes. Ann Surg 2015;261:353-360

© Copyright 2021 Intera Oncology. All Right Reserved Designed by Medtech Momentum